Assessment of atrial electromechanical delay and left atrial mechanical functions in chronic kidney disease

Abstract

The risk of atrial fibrillation (AF) development was revealed to be increased in patients with end-stage renal disease (ESRD) Elongation of the time of atrial electromechanical delay (AEMD) is a famous typical of the atrium. AEMD is a risk factor for AF development and it could be associated with chronic kidney disease (CKD). The aim of our study is to examine mechanical functions of the left atrium (LA) and AEMD times in ESRD. A total of 86 participant, 46 with ESRD and 40 as the control group, were included in the study. The demographical and laboratory information were documented. Echocardiographic dimensions were achieved in all patients. Left atrial mechanical functions and AEMD durations were calculated. Demographic and laboratory characteristics of the groups were similar except the mean diastolic blood pressure, hemoglobin, creatinine, glucose, uric acid, calcium and potassium levels. The echocardiographic assessment exposed that the ventricular septal thickness (12.7±1.5 vs. 10.4±1.5, p<0.001), posterior wall thickness (12.6±1.6 vs. 10.1±1.9, p<0.001), LA dimension (40.9±5.3 vs.34.6±2.6, p<0.001) and diastolic parameters decreased in the ESRD group when compared to the control group; also, LA volumes, mechanical functions, inter atrial EMD (33.2±9.1 vs. 22.7±7.7, p<0.001), intra-right-EMD (18.5±7.7 vs. 13.2±6.4, p=0.001) and intra-left-EMD (18.5±7.7 vs. 13.7±5.7, p=0.002) were also different between groups. (p<0.005) The correlation analysis showed that serum ferritin levels were correlated with AEMD. We found deteriorated LA functions and elongation in the times of AEMD in the ESRD group compared with the control group. Additionally, we found positive correlation between ferritin levels and AEMD. This result show that AEMD might be used to predict the risk of development of AF in patients with ESRD.

Keywords

• Atrial electromechanical delay,Atrial fibrillation,Echocardiography,End-stage renal disease

References

1. Alvaro, A., Faye, L., Lopez, M., 2011. Chronic kidney disease is associated with the incidence of atrial fibrillation the atherosclerosis risk in communities (ARIC) study. Circulation. 123, 2946-2953.
2. Aydın, M., Ozeren, A., Bilge, M., Dursun, A., Cam, M., Elbey, M.A., 2004. Effects of dipper and non-dipper status of essential hypertension on left atrial mechanical functions. International Journal of Cardiology. 96, 419-424.
3. Bishu, K., Agarwal, R., 2006. Acute injury with intravenous iron and concerns regarding long-term safety. Clin. J. Am. Soc. Nephrol. 1, 19-23.
4. Borawski, J., Gozdzikiewicz, J., Abramowicz, P., Naumnik, B., Mysliwiec, M., 2004. Endothelial injury markers with high dose intravenous iron therapy in renal failure. Clin. Appl. Thromb. Hemost. 10, 403-406.
5. Chan, C.T., Levin, N.W., Chertow, G.M., 2010. Determinants of cardiac autonomic dysfunction in ESRD. Clin. J. Am. Soc. Nephrol. 5, 1821-1827.
6. Dabrowska-Kugacka, A., Lewicka-Nowak, E., Ruciński, P., 2009. Atrial electromechanical sequence and contraction synchrony during single-and multisite atrial pacing in patients with brady- tachycardia syndrome. Pacing. Clin. Electrophysiol. 32, 591- 603.
7. Deniz, A., Sahiner, L., Aytemir, K., 2012. Tissue Doppler echocardiography can be a useful technique to evaluate atrial conduction time. Cardiol. J. 19, 487-493.
8. Emiroglu, M.Y., Bulut, M., Sahin, M., 2011. Assessment of atrial conduction time in patients with essential hypertension. J. Electrocardiol. 44, 251-256.

9. Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., 2001. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 285, 2370-2375.
10. Hart, R.G., 2000. Stroke prevention in atrial fibrillation. Curr. Cardiol. Rep. 2, 51-55.
11. Karavelioglu, Y., Karapınar, H., Ozkurt. S., 2014. Evaluation of atrial electromechanical coupling times in hemodialysis patients. Echocardiography. 31, 449-455.
12. Korantzopoulos, P.G., Goudevenos, J.A., 2009. Atrial fibrillation in end-stage renal disease: An emerging problem. Kidney Int. 76, 247-249.
13. Quinones, M.A., Otto, C.M., Stoddard, M., Waggoner, A., Zoghbi, W.A., 2002. Recommendations for quantification of Doppler echocardiography: A report from the doppler quantification task force of the nomenclature and standards committee of the American society of echocardiography. J. Am. Soc. Echocardiogr. 15, 167-184
14. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag, M.J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D.J., Wilson, P.W., 2003. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American heart association councils on kidney in cardiovascular disease, huigh blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 108, 2154-2169.
15. Siragy, H.M., Carey, R.M., 2010. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 31, 541-550.
16. Tekcea, H., Ozturk, S., Aktas G., 2013. The effects of a single dialysis session on atrial electromechanical conduction times and functions. Kidney Blood Press Res. 37, 622-630.
17. To, A.C., Yehia, M., Collins, J.F., 2007. Atrial fibrillation in haemodialysis patients: Do the guidelines for anticoagulation apply? Nephrology. 12, 441-447.
18. Turkmen, K., Demirtas, L., Topa E., 2015. Predictive value of atrial electromechanical delay on long-term cardiovascular outcomes in hemodialysis patients. Am. J. Nephrol. 42, 239-249.
19. Williams, J.R., 2008. The Declaration of Helsinki and public health. Bulletion of the World Health Organization. 86, 650-651.
20. Winkelmayer, W.C., Patrick, A.R., Liu, J., 2011. The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 22, 349-357.